Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
РУДН, Москва
Список исп. литературыСкрыть список 1. Васюк Ю.А., Довженко Т.В., Школьник Е.Л., Ющук Е.В. Депрессия и хроническая сердечная недостаточность при сердечно-сосудистых заболеваниях. М., 2008. 2. Верткин А.Л., Тополянский А.В., Любшина О.В. Применение антидепрессантов в кардиологии. Лечащий врач. 2001; 7: 34–9. 3. Доклад о состоянии здравоохранения в мире. ВОЗ, 2002. 4. Довженко Т.В. Расстройства депрессивного спектра с кардиалгическим синдромом у больных сердечно-сосудистыми заболеваниями (клиника, диагностика, терапия). Дис... докт. мед. наук. М., 2008 5. Дробижев М.Ю. Психофармакотерапия в общесоматической сети (соматотропные эффекты, совместимость с соматотропными препаратами). Психиат. и психофармакотер. 2000; 2 (2): 49–52. 6. Дробижев М.Ю., Дробижева К.Ю. Клинико-экономический анализ программы КОМПАС. Обозрение психиатрии и медицинской психологии им. М.В.Бехтерева. 2006; 1(03): 12–7. 7. Злоказова М.В. Опыт применения Вальдоксана при лечении умеренных и тяжелых депрессивных расстройств непсихотического уровня у амбулаторных пациентов. Психиат. и психофармакотер. 2009; 4: 39–41. 8. Иванов С.В. Вальдоксан (агомелатин) при терапии умеренныХ и тяжелых депРессий непсихОтического уровНя в амбулатОрной и гоСпитальной практике (результаты Российского мультицентрового исследования «ХРОНОС»). Психиат. и психофармакотер 2009; 6: 14–7 9. Концевой В.А., Яковлева О.Б., Сафарова Т.П., Шешенин В.С. Использование ципрамила при лечении депрессий в старости. Психиат. и психофармакотер. 2003; 2 (5): 68–71. 10. Медведев В.Э., Добровольский А.В. Лечение депрессий у больных сердечно-сосудистыми заболеваниями. Опыт применения Велаксина. Психиат. и психофармакотер. 2007; 3: 23–7. 11. Медведев В.Э., Копылов Ф.Ю., Макух Е.А. Терапия депрессий при гипертонической болезни (на моделе препарата Плизил). Психические расстройства в общей медицине. 2008; 4: 43–8. 12. Оганов Р.Г., Масленникова Г.Я. Смертность от сердечно-сосудистых и других хронических неинфекционных заболеваний среди трудоспособного населения России. Кардиоваск. тер. и проф. 2002; 3: 4–8. 13. Погосова Г.В. Депрессия — новый фактор риска ишемической болезни сердца и предиктор коронарной смерти. Кардиология. 2002; 4: 86–91. 14. Смулевич А.Б. Депрессии при соматических и психических заболеваниях. М., 2003. 15. Смулевич А.Б. Клинико-фармакологические эффекты антидепрессантов. Психиат. и психофармакотер. 2003 (Приложение №1): 3–6. 16. Смулевич А.Б., Сыркин А.Л., Дробижев М.Ю., Иванов С.В. Психокардиология. М., 2005. 17. Счастный Е.Д., Зражевская И.А. Применение инновационного антидепрессанта Вальдоксана (агомелатин) при лечении пациента с быстроциклическим течением биполярного аффективного расстройства (клинический случай). Психиат. и психофармакотер. 2009; 5: 22–5. 18. Сыркин А.Л., Медведев В.Э., Троснова А.П., Добровольский А.В. Терапия депрессивных расстройств в кардиологической практике (опыт применения препарата Опра). Психические расстройства в общей медицине. 2006; 2: 28–31. 19. Тимофеева Т.Н., Шальнова С.А., Константинов В.В. и др. Распространенность факторов, влияющих на прогноз больных артериальной гипертонией, и оценка общего сердечно-сосудистого риска. Кардиоваск. тер. и проф. 2005; 6, Часть1: 5–9. 20. Федеральное руководство по использованию лекарственных средств. Формулярная система, 2003. 21. Ades PA, Huang D, Weaver SO. Cardiac rehabilitation participation predicts lower rehospitalization costs. Am Heart J 1992; 123 (4 Pt 1): 916–21. 22. Ariyo AA, Haan M, Tangen CM et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000; 102 (15): 1773–9. 23. Audinot V, Mailliet F, Lahaye-Brasseur C et al. New selective ligands of human cloned melatonin MTI and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 553–61. 24. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93 (11): 1976–80. 25. Bánki MC. Agomelatine: the first «melatoninergic» antidepressant. Neuropsychopharmacol Hung 2006; 8 (3): 105–12. 26. Boivin DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J Psychiatry Neurosci 2000; 25 (5): 446–58. 27. Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52 (4): 174–6. 28. Cross-national comparisons of the prevalences and correlates of mental disorders. Bull WHO 2000; 4 (78): 413–26. 29. Degner D, Grohmann R, Kropp S et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 (Suppl. 1): 39–45. 30. Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 2009; 18 (10): 1533–40. 31. European Medicines Agency. CMHP Assessment Report For Valdoxan.URL:http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-en6.pdf. Accessed November 20, 2008. 32. European Medicines Agency. Committee For Medicinal Products For Human Use Summary of Positive Opinion for Valdoxan. URL: http://www.emea.europa.eu/pdfs/human/opinion/Valdoxan_57541108en.pdf. Accessed November 20, 2008. 33. European Medicines Agency. Valdoxan Product Information. Summary of Product Characteristics. URL:http://www.emea.europa.eu/ humandocs/ PDFs/EPAR/valdoxan/H-915-PI-en.pdf. 34. Goodwin GM, Rouillon F, Emsley R. Long-term treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months [abstract]. In: 21st European College of Neuropsychopharmacology Congress; 30 Aug – 3 Sept 2008; Bareelone. Spain. Eur Neuropsychophar-macol 2008; 18: 338–9. 35. Hartigan-Go K, Bateman DN, Nyberg G et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996; 60 (5): 543–53. 36. Hugues FC, Munera Y, Le Jeunne C. Drug induced orthostatic hypotension. Rev Med Interne 1992; 13 (6): 465–70. 37. Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatric Disease and Treatment 2009; 5: 563–76. 38. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997; 54: 989–91. 39. Kasper S, Lemoine P. Comparative efficacy of the antidepressants agomelatine, venlafaxine and sertraline [abstract]. In: 21st European College of Neuropsycho-pharmacology Congress; 30 Aug-3 Sept 2008; Bareelone, Spain. Eur Neuropsychopharmacol 2008; 18: 331–2. 40. Kielholz P. Masked depression. Bern: Hans Huber 1973. 41. Kennedy SH. Efficacy of agomelatine from treatment initiation to treatment completion [abstract]. In: 21st European College of Neuropsychopharmacology Congress; 30 Aug – 3 Sept 2008; Barcelona. Spain. Eur Neuropsychopharmacol 2008; 18 (Suppl. 4): 293. 42. Kennedy SH. Agomelatine. Efficacy at Each Phase of Antidepressant Treatment. CNS Drugs 2009; 23 (Suppl. 2): 41–7. 43. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100. 44. Kennedy S, Loo H, Olie JP. The antidepressant efficacy of agomelatine is independent of gender, age, body mass index and use of concomitant anxiolytics: combined analysis of three placebo-controlled studies [abstract]. In: 26th Collegium Internationale Neuro-Psychopharmacologicum Congress; 13–17 July 2008; Munich, Germany. Int J Neuropsychopharmacol 2008; 11 (Suppl. I): 193. 45. Kennedy SH, Rizvi S, Fulton K et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329–33. 46. Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007; 67: 1657–63. 47. Lane RM, Sweeney M, Henry JA. Pharmacotherapy of the depressed patient with cardiovascular and/or cerebrovascular illness. Br J Clin Pract 1994; 48 (5): 256–62. 48. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32. 49. Lespérance F, Frasure-Smith N. Sertraline for treatment of depression in acute coronary syndromes. JAMA 2002; 288 (19): 2403; author reply 2403–4. 50. Lischke V, Wilke HJ, Probst S et al. Prolongation of the QT-interval during induction of anesthesia in patients with coronary artery disease. Acta Anaesthesiol Scand 1994; 38 (2): 144–8. 51. Loo H, Hale A, D\'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47. 52. Lôo H, Daléry J, Macher JP, Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale 2003; 29 (2): 165–71. 53. Lopez AA, Bragg J, Young E еt al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in United States and Europe. Kidney Int 2002; 62 (1): 199–207. 54. McClung CA. Circadian rhythms, the mesolimbic dopaminergic circuit, and drug addiction. Scientific World Journal 2007; 7: 194–202. 55. McFarlane A, Kamath MV, Fallen EL et al. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 2001; 142: 617–23. 56. Mets TF. Drug-induced orthostatic hypotension in older patients. Drugs Aging 1995; 6 (3): 219–28. 57. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydro-xytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–64. 58. Montgomery SA, Kennedy SH, Burrows GD et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19 (5): 271–80. 59. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283–91. 60. Moses HW, Yu PN. Antiarrhythmic drugs. J Clin Pharmacol 1980; 20 (10): 598–618. 61. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994; 55 (Suppl.): 3–15; discussion 16–7. 62. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661–73. 63. Owen RT. Agomelatine: A novel pharmacological approach to treating depression. Drugs Today (Barc) 2009; 45 (8): 599–608. 64. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008; 69 (Suppl. El): 8–13. 65. Quera-Salva MA, Vanier B, Chapotot F. Effect of agomelatine on the sleep EEG in patients with major depressive disorder. Eur Neuropsychopharmacol 2005; 15 (Suppl. 3): 435–6. 66. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003; 54 (3): 227–40. 67. Ruo B, Rumsfeld JS, Hlatky MA et al. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290(2) Jul 9: 215–21. 68. Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231–42. 69. Saitz Ruiz J, Ibanez Cuadrado A. Diagnosis of depressive equivalents. Rev Clin Esp 2002; 202 (2): 88–90. 70. Schulberg HC, Block MR, Madonia MJ et al. Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 1996; 53: 913–9. 71. Strik JJ, Lousberga R, Cheriexb EC, Honiga A. One year cumulative incidence of depression following myocardial infarction and impact on cardiac outcome. J Psychosomatic Research 2004; 56: 59–66. 72. Tessmer M. Agomelatine. Med Monatsschr Pharm 2009; 32 (8): 282–8. 73. Turek FW. From circadian rhythms to clock genes in depression. Int Clin Psychopharmacol 2007; 22 (Suppl. 2): 1–8. 74. Ustin T, Sartorius N. 1995 Preventive Services Task Forse: Guide to Clinical Preventive Services. 2nd Ed. Washington, DC:U.S. Department of Health and Human Services., 1999. 75. von Zerssen D, Dirlich G, Doerr P et al. Are biological rhythms disturbed in depression? Acta Psychiatr Belg 1985; 85 (5): 624–35. 76. Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 20 (12): 981–92. 77. Wang PS, Patrick AR, Dormuth CR et al. The impact of cost sharing on antidepressant use among older adults in British Columbia. Psychiatr Serv 2008; 59 (4): 377–83.